Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Post-Mkt 11-10 17:28:31 EST

4.10

-0.19

-4.43%

盘后4.06

-0.04-1.06%

17:10 EST

High4.23	Low4.01	Vol928.40K
Open4.20	D1 Closing4.29	Amplitude5.13%
Mkt Cap128.29M	Tradable Cap83.89M	Total Shares31.29M
T/O3.82M	T/O Rate4.54%	Tradable Shares20.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":4.1,"timestamp":1794344400000,"preClose":4.29,"halted":0,"volume":928401,"hourTrading":{"tag":"盘后","latestPrice":4.0565,"preClose":4.1,"latestTime":"17:10 EST","volume":3682,"amount":15089.84855,"timestamp":1794348656326,"change":-0.0435,"changeRate":-0.01061,"amplitude":0.01061},"delay":0,"changeRate":-0.04428904428904438,"floatShares":20461200,"shares":31289969,"eps":-4.482297,"marketStatus":"Post-Mkt","change":-0.19,"latestTime":"11-10 17:28:31 EST","open":4.2,"high":4.23,"low":4.01,"amount":3822680.3480484,"amplitude":0.051282,"askPrice":4.14,"askSize":200,"bidPrice":4.05,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-4.482297,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1794358800000},"marketStatusCode":4,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":4.29,"preHourTrading":{"tag":"盘前","latestPrice":4.1895,"preClose":4.29,"latestTime":"09:05 EST","volume":1140,"amount":4789.184802,"timestamp":1794319516936,"change":-0.1005,"changeRate":-0.023427,"amplitude":0.088578},"postHourTrading":{"tag":"盘后","latestPrice":4.0565,"preClose":4.1,"latestTime":"17:10 EST","volume":3682,"amount":15089.84855,"timestamp":1794348656326,"change":-0.0435,"changeRate":-0.01061,"amplitude":0.01061},"volumeRatio":0.791637,"impliedVol":1.9937,"impliedVolPercentile":0.749},"requestUrl":"/m/hq/s/LENZ/tweets","defaultTab":"tweets","newsList":[{"id":"2682196344","title":"Context Therapeutics Reports Q3 Results and CTIM-76 Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2682196344","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682196344?lang=en_us&edition=fundamental","pubTime":"2026-11-11 06:11","pubTimestamp":1794348681,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Context Therapeutics ( ($CNTX) ). On November 10, 2026, Context Therapeutics reported third-quarter results and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-reports-q3-results-and-ctim-76-trial-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-reports-q3-results-and-ctim-76-trial-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","LENZ","LU2065732104.USD","BK4539","BK4139","BK4007","CNTX","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682341273","title":"Context Therapeutics reports Q3 EPS (8c), consensus (11c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2682341273","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682341273?lang=en_us&edition=fundamental","pubTime":"2026-11-11 06:00","pubTimestamp":1794348023,"startTime":"0","endTime":"0","summary":"“CTIM-76 continues to show promising activity in patients with PROC who had received a median of six prior lines of therapy,” said Martin Lehr, Chi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/context-therapeutics-reports-q3-eps-8c-consensus-11c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/context-therapeutics-reports-q3-eps-8c-consensus-11c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682346764","title":"Press Release: Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2682346764","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682346764?lang=en_us&edition=fundamental","pubTime":"2026-11-11 05:16","pubTimestamp":1794345360,"startTime":"0","endTime":"0","summary":"CTIM-76 weekly dosing at 140--280 ug in heavily pretreated PROC: 22% confirmed ORR,56% confirmed DCR, and median PFS of 5.6 monthsDose escalation to 420 ug every three weeks is ongoing following compl","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","PRGS","LENZ","R","BK4232","BK4022","BK4539","BK4097","BK4007","LU2065732104.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682346629","title":"Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2682346629","media":"GlobeNewswire","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682346629?lang=en_us&edition=fundamental","pubTime":"2026-11-11 05:05","pubTimestamp":1794344700,"startTime":"0","endTime":"0","summary":"FDA clearance enables initiation of a first-in-human Phase 1/2 trial of MGX-001 in patients with hemophilia A MGX-001 is designed to deliver durable, endogenous Factor VIII (FVIII) activity from a one","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/11/10/3400201/0/en/metagenomi-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-mgx-001-and-reports-third-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ASH.AU","BK4588","BK4007","BK7057","LABU","LENZ","BK4585","BK9077","IND","MGX","BK4139","IND.AU","BK4109","BK7095","032820.KR","ASH","LU2463526074.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682343759","title":"Maze Therapeutics: Buy Rating Maintained with $110 Price Target Unchanged on MZE829’s Strong Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2682343759","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682343759?lang=en_us&edition=fundamental","pubTime":"2026-11-11 04:25","pubTimestamp":1794342335,"startTime":"0","endTime":"0","summary":"In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Maze Therapeutics, Inc., with a price target of $110.00. A...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/maze-therapeutics-buy-rating-maintained-with-110-price-target-unchanged-on-mze829s-strong-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/maze-therapeutics-buy-rating-maintained-with-110-price-target-unchanged-on-mze829s-strong-potential-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682170310","title":"Rani Therapeutics: Buy Rating Reaffirmed on Strong Q3, Extended Cash Runway and RT-114 Catalyst; $5 Price Target Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2682170310","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682170310?lang=en_us&edition=fundamental","pubTime":"2026-11-11 02:26","pubTimestamp":1794335188,"startTime":"0","endTime":"0","summary":"Edward Nash, an analyst from Canaccord Genuity, maintained the Buy rating on Rani Therapeutics Holdings. The associated price target remains the sa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/rani-therapeutics-buy-rating-reaffirmed-on-strong-q3-extended-cash-runway-and-rt-114-catalyst-5-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/rani-therapeutics-buy-rating-reaffirmed-on-strong-q3-extended-cash-runway-and-rt-114-catalyst-5-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682317541","title":"Trevi Therapeutics reports Q3 EPS (13c), consensus (13c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2682317541","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682317541?lang=en_us&edition=fundamental","pubTime":"2026-11-11 01:41","pubTimestamp":1794332490,"startTime":"0","endTime":"0","summary":"“This is an important time of clinical execution for Trevi as we actively open sites globally and enroll patients across all three active trials,” ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/trevi-therapeutics-reports-q3-eps-13c-consensus-13c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/trevi-therapeutics-reports-q3-eps-13c-consensus-13c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682317547","title":"Maze Therapeutics reports Q3 EPS (79c), consensus (75c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2682317547","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682317547?lang=en_us&edition=fundamental","pubTime":"2026-11-11 01:41","pubTimestamp":1794332470,"startTime":"0","endTime":"0","summary":"Reports Q3 net loss $48.0M vs. $30.1M last year. Cash, cash equivalents and marketable securities were $477.0M as of September 30, which the compan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-reports-q3-eps-79c-consensus-75c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-reports-q3-eps-79c-consensus-75c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682317554","title":"Maze Therapeutics completes enrollment in Phase 2 HORIZON trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2682317554","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682317554?lang=en_us&edition=fundamental","pubTime":"2026-11-11 01:41","pubTimestamp":1794332465,"startTime":"0","endTime":"0","summary":"Maze Therapeutics (MAZE) announced that enrollment is complete in the Phase 2 HORIZON trial evaluating MZE829 in more than 50 patients with APOL1-m...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-completes-enrollment-in-phase-2-horizon-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/maze-therapeutics-completes-enrollment-in-phase-2-horizon-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","MAZE","LENZ","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682317516","title":"Rani Therapeutics reports Q3 EPS (4c), consensus (5c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2682317516","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682317516?lang=en_us&edition=fundamental","pubTime":"2026-11-11 01:39","pubTimestamp":1794332396,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $1.71M, consensus $1.28M. “The third quarter marked continued progress for the RaniPill platform and, most recently, our accepta...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rani-therapeutics-reports-q3-eps-4c-consensus-5c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rani-therapeutics-reports-q3-eps-4c-consensus-5c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682398317","title":"ADC Therapeutics' Revenue Growth Outlook Remains Unclear, RBC Capital Markets Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2682398317","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682398317?lang=en_us&edition=fundamental","pubTime":"2026-11-11 01:39","pubTimestamp":1794332344,"startTime":"0","endTime":"0","summary":"ADC Therapeutics'  recent restructuring improved the company's financial position and its Lotis-7 data looked encouraging, but outlook for revenue growth remains unclear given the competitive landscape in diffuse large B-cell lymphoma, RBC Capital Markets said in a note Monday.The company reported Q3 revenue at the high end of Zynlonta's historical range, as previously announced, while maintaining good control over expenses, the investment firm said.The company has a potential path forward, but the Lotis-7 data remains immature, RBC said, adding that additional data from subgroups could help contextualize the drug in the \"highly competitive\" DLBCL landscape.RBC Capital Markets has a sector perform, speculative risk rating on ADC Therapeutics, with a $2 price target.Shares of ADC Therapeutics were down 9.6% in Tuesday trading.Price: 1.51, Change: -0.16, Percent Change: -9.58","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682124023","title":"ADC Therapeutics registers to sell 61M common shares for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2682124023","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682124023?lang=en_us&edition=fundamental","pubTime":"2026-11-11 01:21","pubTimestamp":1794331290,"startTime":"0","endTime":"0","summary":"This filing relates to the offer and sale from time to time by the selling stockholders of up to 61M common shares. The company is not selling any ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adc-therapeutics-registers-to-sell-61m-common-shares-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adc-therapeutics-registers-to-sell-61m-common-shares-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682124773","title":"Tango Therapeutics price target lowered to $67 from $68 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2682124773","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682124773?lang=en_us&edition=fundamental","pubTime":"2026-11-11 01:20","pubTimestamp":1794331212,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Tango Therapeutics (TNGX) to $67 from $68 and keeps a Buy rating on the sha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tango-therapeutics-price-target-lowered-to-67-from-68-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tango-therapeutics-price-target-lowered-to-67-from-68-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682312613","title":"Tango Therapeutics is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2682312613","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682312613?lang=en_us&edition=fundamental","pubTime":"2026-11-11 01:11","pubTimestamp":1794330660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TNGX/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682128033","title":"Structure Therapeutics price target lowered to $107 from $111 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2682128033","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682128033?lang=en_us&edition=fundamental","pubTime":"2026-11-11 00:56","pubTimestamp":1794329787,"startTime":"0","endTime":"0","summary":"Canaccord lowered the firm’s price target on Structure Therapeutics (GPCR) to $107 from $111 and keeps a Buy rating on the shares. The firm said St...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-price-target-lowered-to-107-from-111-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-price-target-lowered-to-107-from-111-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682314431","title":"Hemab Therapeutics reports Q3 EPS (58c), consensus (52c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2682314431","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682314431?lang=en_us&edition=fundamental","pubTime":"2026-11-11 00:42","pubTimestamp":1794328920,"startTime":"0","endTime":"0","summary":"“We are excited to have started our Phase 3 study in Glanzmann thrombasthenia, transitioning Hemab to a biotech company with clinical stage program...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-reports-q3-eps-58c-consensus-52c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hemab-therapeutics-reports-q3-eps-58c-consensus-52c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682141213","title":"Beam Therapeutics reports BEACON trial achieves primary efficacy endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2682141213","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682141213?lang=en_us&edition=fundamental","pubTime":"2026-11-11 00:41","pubTimestamp":1794328896,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) announced topline results from the BEACON Phase 1/2 study evaluating ristoglogene autogetemcel in patients with sickle cel...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-reports-beacon-trial-achieves-primary-efficacy-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-reports-beacon-trial-achieves-primary-efficacy-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4585","LU1861559042.SGD","BK4556","BEAM","BK4007","LU1861558580.USD","BK4611","BK4139","BK4588","LENZ","BK4535","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682314901","title":"Wedbush Raises Price Target on Beam Therapeutics to $33 From $30, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2682314901","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682314901?lang=en_us&edition=fundamental","pubTime":"2026-11-11 00:38","pubTimestamp":1794328723,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) has an average rating of buy and mean price target of $48.71, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682311651","title":"Trevi Therapeutics: Buy Rating Reaffirmed as Chronic-Cough Pipeline Advances; $28 Price Target Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2682311651","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682311651?lang=en_us&edition=fundamental","pubTime":"2026-11-10 23:37","pubTimestamp":1794325033,"startTime":"0","endTime":"0","summary":"Analyst Debanjana Chatterjee of JonesTrading maintained a Buy rating on Trevi Therapeutics, retaining the price target of $28.00. Debanjana Chatter...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/trevi-therapeutics-buy-rating-reaffirmed-as-chronic-cough-pipeline-advances-28-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/trevi-therapeutics-buy-rating-reaffirmed-as-chronic-cough-pipeline-advances-28-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682319041","title":"Maze Therapeutics Price Target Raised to $49.00/Share from $48.00 by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2682319041","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682319041?lang=en_us&edition=fundamental","pubTime":"2026-11-10 23:25","pubTimestamp":1794324300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MAZE/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":0.4066},{"period":"1month","weight":0.177},{"period":"3month","weight":-0.1766},{"period":"6month","weight":-0.4671},{"period":"1year","weight":-0.8132},{"period":"ytd","weight":-0.7319}],"compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0332},{"period":"3month","weight":-0.0232},{"period":"6month","weight":0.014},{"period":"1year","weight":0.1218},{"period":"ytd","weight":0.1038}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.134259},{"month":6,"riseRate":0.6,"avgChangeRate":-0.009929},{"month":7,"riseRate":0.5,"avgChangeRate":0.033083},{"month":8,"riseRate":0.333333,"avgChangeRate":0.01095},{"month":9,"riseRate":0.5,"avgChangeRate":-0.02143},{"month":10,"riseRate":0.5,"avgChangeRate":-0.090577},{"month":11,"riseRate":0.666667,"avgChangeRate":0.063217},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}